NCT04408183View on ClinicalTrials.gov

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

PHASE2TerminatedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

June 10, 2020

Primary Completion Date

January 10, 2023

Study Completion Date

January 10, 2023

Conditions
SARS-CoV 2Infection
Interventions
DRUG

GLS-1200

GLS-1200 is given as a nasal spray using an atomizer

DRUG

Placebo

Placebo is given as a nasal spray using an atomizer

Trial Locations (3)

19104

University of Pennsylvania, Philadelphia

70809

Sinus and Nasal Specialists of Louisiana, Baton Rouge

77304

Conroe Willis Medical Reasearch, Conroe

Sponsors
All Listed Sponsors
lead

GeneOne Life Science, Inc.

INDUSTRY

NCT04408183 - GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) | Biotech Hunter | Biotech Hunter